(Q34024866)

30 July 2017

Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India (English)

1 reference

30 July 2017

0 references

visceral leishmaniasis

1 reference

1 reference

Prabhat K Sinha

1

1 reference

30 July 2017

Paul Roddy

2

1 reference

30 July 2017

Pedro Pablo Palma

3

1 reference

30 July 2017

Alice Kociejowski

4

1 reference

30 July 2017

María Angeles Lima

5

1 reference

30 July 2017

Vidya Nand Rabi Das

6

1 reference

30 July 2017

Jitendra Gupta

7

1 reference

30 July 2017

Nawin Kumar

8

1 reference

30 July 2017

Gaurab Mitra

9

1 reference

30 July 2017

Jean-François Saint-Sauveur

10

1 reference

30 July 2017

Siju Seena

11

1 reference

30 July 2017

Manica Balasegaram

12

1 reference

30 July 2017

Fernando Parreño

13

1 reference

30 July 2017

Krishna Pandey

14

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

American Journal of Tropical Medicine and Hygiene

30 July 2017

1 reference

30 July 2017

83

1 reference

30 July 2017

357-364

1 reference

30 July 2017

2

1 reference

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Injectable paromomycin for Visceral leishmaniasis in India

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Liposomal amphotericin B for the treatment of visceral leishmaniasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Development of miltefosine as an oral treatment for leishmaniasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Leishmaniasis: current situation and new perspectives

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Recent understanding in the treatment of visceral leishmaniasis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Advances in the treatment of leishmaniasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Oral miltefosine for Indian visceral leishmaniasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Availability of miltefosine for the treatment of kala-azar in India.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Deaths in visceral leishmaniasis (Kala-azar) during treatment

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911185

Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20682882

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4269/AJTMH.2010.10-0156

1 reference

30 July 2017

1 reference

30 July 2017

1 reference